A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics and Efficacy of Isatuximab in Combination With Cemiplimab in Patients With Relapsed/Refractory Multiple Myeloma
Latest Information Update: 17 Jun 2024
At a glance
- Drugs Cemiplimab (Primary) ; Isatuximab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 18 Apr 2023 Status changed from active, no longer recruiting to completed.
- 03 Apr 2023 Planned End Date changed from 31 Mar 2023 to 5 Apr 2023.
- 03 Apr 2023 Planned primary completion date changed from 31 Mar 2023 to 5 Apr 2023.